CAS number ,  (HCl)
Jmol-3D images Image 1
Molecular formula C16H24N2O4
Molar mass 308.37 g mol−1
Melting point 245 °C (473 °F) (dec.)
S-phrases S22 S24/25
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 YesY   YesY/N?)

Ubenimex (INN), also known by the brand name bestatin, is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B,[2] leukotriene A4 hydrolase,[3] and aminopeptidase N.[4] It is being studied for use in the treatment of acute myelocytic leukemia.[5] It is derived from Streptomyces olivoreticuli.[6]

Crystal structure of ubenimex
Crystal structure of ubenimex in the binding pocket of leukotriene A4 hydrolase. Rendered from PDB 1HS6.


  1. ^ N-((2S,3R)-3-Amino-2-hydroxy-4-phenylbutyryl)-L-leucine at Sigma-Aldrich
  2. ^ Umezawa,H., Aoyagi,T., Suda,H., Hamada,M. & Takeuchi,T. (1976). "Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes." (29). pp. 97–99. 
  3. ^ Muskardin,D.T., Voelkel,N.F. & Fitzpatrick,F.A. (1994). "Modulation of pulmonary leukotriene formation and perfusion pressure by bestatin, an inhibitor of leukotriene A4 hydrolase." (48). pp. 131–137. 
  4. ^ K Sekine, H Fujii and F Abe (1999). "Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines" 13 (5). pp. 729–734. 
  5. ^ Hirayama, Y; Sakamaki, S; Takayanagi, N; Tsuji, Y; Sagawa, T; Chiba, H; Matsunaga, T; Niitsu, Y (2003). "Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival". Gan to kagaku ryoho. Cancer & chemotherapy 30 (8): 1113–8.  
  6. ^ Bauvois, B; Dauzonne, D (January 2006). "Aminopeptidase-N/CD13 (EC inhibitors: Chemistry, biological evaluations, and therapeutic prospects". Medicinal Research Reviews 26 (1): 88–130.  

External links

  • The MEROPS online database for peptidases and their inhibitors: Bestatin